The abstract is read at the publisher; the summary is JClub's.
Hereditary haemorrhagic telangiectasia remains without licensed therapies worldwide, despite a high global burden and rapid development of multiple investigational vascular and haemostatic agents.
- Why it matters: The disorder is a morbid autosomal dominant vasculopathy linked to dysregulated angiogenic signalling, producing telangiectasias and arteriovenous malformations with chronic bleeding, anemia, intracranial haemorrhage, and other complications.
- What they did: This comprehensive Review summarizes hereditary haemorrhagic telangiectasia pathophysiology and provides focused discussions of novel agents in development, including engasertib, ATV-1601, TER-4480, ALN-6400, DIAG723, and TX2100.
- The result: By detailing mechanisms, therapeutic rationale, and clinical trial programmes for each agent, the Review clarifies potential therapeutic effects and supports ongoing formal development in hereditary haemorrhagic telangiectasia.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.